Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-21
DOI
10.1038/s41388-018-0597-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors
- (2018) Norimichi Chiyonobu et al. AMERICAN JOURNAL OF PATHOLOGY
- Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma
- (2017) Kyle J. Thompson et al. LIVER INTERNATIONAL
- Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis
- (2016) F. Cauchy et al. CLINICAL SCIENCE
- NAFLD and liver transplantation: Current burden and expected challenges
- (2016) Raluca Pais et al. JOURNAL OF HEPATOLOGY
- Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins
- (2016) Sandra Guaita-Esteruelas et al. MOLECULAR CARCINOGENESIS
- New insights into circulating FABP4: Interaction with cytokeratin 1 on endothelial cell membranes
- (2015) Paula Saavedra et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- (2015) Robert J. Wong et al. GASTROENTEROLOGY
- Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome
- (2015) François Cauchy et al. GUT
- Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles
- (2015) Sara Lemoinne et al. HEPATOLOGY
- Fatty acid binding protein-4 (FABP4) is a hypoxia inducible gene that sensitizes mice to liver ischemia/reperfusion injury
- (2015) Bingfang Hu et al. JOURNAL OF HEPATOLOGY
- Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms
- (2015) Mackenzie Herroon et al. Oncotarget
- Fatty Acid-binding Protein 4, a Point of Convergence for Angiogenic and Metabolic Signaling Pathways in Endothelial Cells
- (2014) Ulrike Harjes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of FDA-Approved Drugs as Inhibitors of Fatty Acid Binding Protein 4 Using Molecular Docking Screening
- (2014) Yan Wang et al. Journal of Chemical Information and Modeling
- Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity
- (2014) Meric Erikci Ertunc et al. JOURNAL OF LIPID RESEARCH
- Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma
- (2014) DOKSA LEE et al. ONCOLOGY REPORTS
- FABP4 Attenuates PPAR and Adipogenesis and Is Inversely Correlated With PPAR in Adipose Tissues
- (2013) T. Garin-Shkolnik et al. DIABETES
- Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway
- (2012) Harun Elmasri et al. ANGIOGENESIS
- Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients
- (2012) Pierre Bedossa et al. HEPATOLOGY
- Cardiometabolic Correlates and Heritability of Fetuin-A, Retinol-Binding Protein 4, and Fatty-Acid Binding Protein 4 in the Framingham Heart Study
- (2012) Bernhard M. Kaess et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
- (2012) György Baffy et al. JOURNAL OF HEPATOLOGY
- Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
- (2011) I. Ben Sahra et al. CANCER RESEARCH
- Cancer-Associated Adipocytes Exhibit an Activated Phenotype and Contribute to Breast Cancer Invasion
- (2011) B. Dirat et al. CANCER RESEARCH
- Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare database
- (2011) Tania M. Welzel et al. HEPATOLOGY
- Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
- (2011) Kristin M Nieman et al. NATURE MEDICINE
- Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection
- (2010) Brad Q. Starley et al. HEPATOLOGY
- Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis
- (2010) Dipali Sharma et al. HEPATOLOGY
- Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects
- (2010) Young-Choon Kim et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- The metabolic syndrome
- (2010) Robert H Eckel et al. LANCET
- Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
- (2009) K. Hancke et al. BREAST CANCER RESEARCH AND TREATMENT
- Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis
- (2009) Valérie Paradis et al. HEPATOLOGY
- Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease
- (2009) Kerry-Lee Milner et al. HEPATOLOGY
- Adipokines in liver diseases
- (2009) Fabio Marra et al. HEPATOLOGY
- Serum Adipocyte Fatty Acid-Binding Protein Levels Are Associated With Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients
- (2008) J. Hyun Koh et al. DIABETES CARE
- Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
- (2008) Masato Furuhashi et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started